The long-term goal is to develop a human therapeutic HER2/Neu-specific EXO-T vaccine using autologous polyclonal T cells with uptake of HER2/Neu-specific autologous DC (DCHER2/Neu)-released EXOs as a novel personalized vaccine for breast cancer [445]. The gene discussed is ERBB2; the disease is breast carcinoma.